Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses
21 9월 2023 - 11:00PM
Business Wire
Altasciences is pleased to have been chosen by Virpax
Pharmaceuticals, Inc. (NASDAQ:VRPX) (“Virpax”), a company
specializing in developing non-addictive products for pain
management, PTSD, central nervous system (CNS) disorders, and viral
barrier indications, to conduct preclinical studies in support of
their development of quaternary ammonium palmitoyl glycol chitosan
(GCPQ, under the trade name of AnQlar™). AnQlar is a nanoparticle
intended to help prevent the spread of negatively charged viruses
such as COVID-19 and influenza via intranasal spray, and has shown
to inhibit the ability of the virus to replicate at non-toxic
concentrations.
In development since 2022, the project has so far seen the
completion of safety assessment utilizing intranasal administration
at Altasciences’ preclinical site in Columbia, MO. A cardiovascular
study was also completed at Altasciences’ preclinical facility in
Scranton, PA.
Bioanalytical sample analysis for the GLP studies is currently
ongoing. “We are very pleased to be working with Virpax again and
are satisfied with the trajectory our studies have taken. The final
step for this program will be a bioanalytical sample analysis. Once
samples are validated, this will conclude the IND package,” said
Kyle Klepner, Senior Scientist, Study Director, Safety Assessment,
Altasciences.
Steve Mason, Co-Chief Operating Officer, Altasciences, added:
“The creation of AnQlar as a treatment, if successful, could be a
huge leap forward in preventing the spread of influenza and similar
viruses. We look forward to further collaboration with Virpax in
the near-future.”
Dr. Sheila Mathias PhD, Chief Scientific Officer, Virpax, also
said of the project: “Our work with Altasciences over the last year
has been both exceedingly productive and rewarding demonstrating
tangible results, and the nonclinical support provided has been
vital in ensuring the progress of this project.”
About Altasciences
Altasciences is an integrated drug development solution company
offering pharmaceutical and biotechnology companies a proven,
flexible approach to preclinical and clinical pharmacology studies,
including formulation, manufacturing, and analytical services. For
over 25 years, Altasciences has been partnering with sponsors to
help support educated, faster, and more complete early drug
development decisions. Altasciences’ integrated, full-service
solutions include preclinical safety testing, clinical pharmacology
and proof of concept, bioanalysis, program management, medical
writing, biostatistics, clinical monitoring, and data management,
all customizable to specific sponsor requirements. Altasciences
helps sponsors get better drugs to the people who need them,
faster. To learn more about Altasciences, visit
altasciences.com.
About Virpax
Virpax is developing branded, non-addictive pain management
products candidates using its proprietary technologies to optimize
and target drug delivery. Virpax is initially seeking FDA approval
for two prescription drug candidates that employ two different
patented drug delivery platforms. Probudur™, a single injection
liposomal bupivacaine formulation being developed to manage
post-operative pain, and Envelta™, an intranasal molecular envelope
enkephalin formulation being developed to manage acute and chronic
pain, including pain associated with cancer.
Virpax is also using its intranasal molecular envelope
technology (MET) to develop two other product candidates. PES200,
is a product candidate being developed to manage PTSD, and
NobrXiol™, a product candidate being developed for the nasal
delivery of a pharmaceutical-grade cannabidiol (CBD), for the
management of rare pediatric epilepsy.
Having recently acquired global rights to NobrXiol, Virpax has
competitive cooperative research and development agreements
(CRADAs) for all three of its prescription drug candidates, two
with the National Institutes of Health (NIH) and one with the
Department of Defense (DOD). Virpax is currently seeking approval
of two nonprescription product candidates: AnQlar, which is being
developed to inhibit viral replication caused by influenza or
SARS-CoV-2, and Epoladerm™, a topical diclofenac spray film
formulation being developed to manage pain associated with
osteoarthritis.
For more information, please visit virpaxpharma.com and follow
us on Twitter, LinkedIn and YouTube.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230921062012/en/
Julie-Ann Cabana Altasciences +1 514 601-9763
jcabana@altasciences.com
Virpax Media: Robert Cavosi RooneyPartners
rcavosi@rooneypartners.com (646) 638-9891
Virpax Pharmaceuticals (NASDAQ:VRPX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Virpax Pharmaceuticals (NASDAQ:VRPX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024